PRE 103

Drug Profile

PRE 103

Latest Information Update: 24 Apr 2007

Price : $50

At a glance

  • Originator Prescient NeuroPharma
  • Class
  • Mechanism of Action Glutamate agonists; Metabotropic glutamate receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 17 Oct 2001 Preclinical development for Stroke in Canada (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top